308 related articles for article (PubMed ID: 27296533)
1. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
[TBL] [Abstract][Full Text] [Related]
2. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
Cazzola M; Calzetta L; Segreti A; Facciolo F; Rogliani P; Matera MG
COPD; 2015 Apr; 12(2):175-81. PubMed ID: 25222881
[TBL] [Abstract][Full Text] [Related]
3. Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis.
Baroffio M; Barisione G; Brusasco V
Respir Res; 2017 Jul; 18(1):145. PubMed ID: 28754132
[TBL] [Abstract][Full Text] [Related]
4. Effects of (a Combination of) the Beta
Maarsingh H; Oldenburger A; Han B; Zuidhof AB; Elzinga CRS; Timens W; Meurs H; Sopi RB; Schmidt M
Cells; 2021 May; 10(5):. PubMed ID: 34069899
[TBL] [Abstract][Full Text] [Related]
5. Interaction between corticosteroids and muscarinic antagonists in human airways.
Cazzola M; Calzetta L; Rogliani P; Puxeddu E; Facciolo F; Matera MG
Pulm Pharmacol Ther; 2016 Feb; 36():1-9. PubMed ID: 26656790
[TBL] [Abstract][Full Text] [Related]
6. Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.
Rogliani P; Ritondo BL; Facciolo F; Matera MG; Nikolaev I; Calzetta L
Pharmacol Res; 2021 Oct; 172():105801. PubMed ID: 34363950
[TBL] [Abstract][Full Text] [Related]
7. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways.
Calzetta L; Cazzola M; Page CP; Rogliani P; Facciolo F; Matera MG
Pulm Pharmacol Ther; 2015 Jun; 32():15-23. PubMed ID: 25899618
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.
Calzetta L; Rogliani P; Page C; Rinaldi B; Cazzola M; Matera MG
Pulm Pharmacol Ther; 2019 Jun; 56():39-50. PubMed ID: 30876907
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.
Cazzola M; Calzetta L; Page CP; Rogliani P; Facciolo F; Gavaldà A; Matera MG
Eur J Pharmacol; 2014 Dec; 745():135-43. PubMed ID: 25446566
[TBL] [Abstract][Full Text] [Related]
11. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.
Rogliani P; Matera MG; Facciolo F; Page C; Cazzola M; Calzetta L
Br J Pharmacol; 2020 Mar; 177(5):1150-1163. PubMed ID: 31660611
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi.
Calzetta L; Rogliani P; Mattei M; Alfonsi P; Cito G; Pistocchini E; Cazzola M; Matera MG
COPD; 2017 Oct; 14(5):526-532. PubMed ID: 28745522
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
[TBL] [Abstract][Full Text] [Related]
14. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study.
Blais CM; Davis BE; Cockcroft DW
Respir Res; 2017 Aug; 18(1):146. PubMed ID: 28768531
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium.
Pelaia G; Maselli R; Matera MG
Pharmacology; 2014; 94(5-6):249-58. PubMed ID: 25471458
[TBL] [Abstract][Full Text] [Related]
16. Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane.
Aritake H; Tamada T; Murakami K; Gamo S; Nara M; Kazama I; Ichinose M; Sugiura H
Pflugers Arch; 2021 Jun; 473(6):883-896. PubMed ID: 34031755
[TBL] [Abstract][Full Text] [Related]
17. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.
Naline E; Trifilieff A; Fairhurst RA; Advenier C; Molimard M
Eur Respir J; 2007 Mar; 29(3):575-81. PubMed ID: 17135231
[TBL] [Abstract][Full Text] [Related]
18. Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
Blair HA
Drugs; 2021 Apr; 81(6):709-719. PubMed ID: 33871819
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the Adverse and Therapeutic Effects of
Yan D; Hamed O; Joshi T; Mostafa MM; Jamieson KC; Joshi R; Newton R; Giembycz MA
J Pharmacol Exp Ther; 2018 Jul; 366(1):220-236. PubMed ID: 29653961
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
